title: Dermatic Scedosporium apiospermum infection after autologous bone marrow transplantation.
abstract: Infection with Scedosporium apiospermum (S. apiospermum) is rare, although it is associated with a high fatality rate, especially in immunosuppressed patients. A 23-year-old man with acute myelogenous leukemia (AML) (M2) who was pretreated with chemotherapy for autologous bone marrow transplantation developed a skin ulcer on the left groin. After a culture study demonstrated the presence of S. apiospermum, voriconazole was administered and the lesion rapidly improved. Since a diagnosis of S. apiospermum continues to depend on the results of a fungal culture and most isolates of S. apiospermum are resistant to amphotericin B, voriconazole should be considered as the first choice when "mold" is thought to be the causative organism.
authors.affiliation: Department of Hematopoietic Stem Cell Transplantation, Affiliated Hospital to Academy of Military Medical Sciences, China. zhiyong__yu@163.com
authors.forename: Zhiyong
authors.initials: Z
authors.lastname: Yu
authors.forename: Liangding
authors.initials: L
authors.lastname: Hu
authors.forename: Min
authors.initials: M
authors.lastname: Jiang
authors.forename: Hongmei
authors.initials: H
authors.lastname: Ning
authors.forename: Chen
authors.initials: C
authors.lastname: Xu
authors.forename: Botao
authors.initials: B
authors.lastname: Li
authors.forename: Yuhang
authors.initials: Y
authors.lastname: Li
authors.forename: Xiao
authors.initials: X
authors.lastname: Lou
authors.forename: Jun
authors.initials: J
authors.lastname: Wang
authors.forename: Jiangwei
authors.initials: J
authors.lastname: Hu
authors.forename: Hu
authors.initials: H
authors.lastname: Chen
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D003881:Dermatomycoses / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000601:surgery; D008297:Male; D008942:Mitoxantrone / Q000008:administration & dosage; D009894:Opportunistic Infections / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology; D011183:Postoperative Complications / Q000188:drug therapy / Q000382:microbiology*; D011743:Pyrimidines / Q000627:therapeutic use; D021681:Scedosporium / Q000302:isolation & purification*; D012883:Skin Ulcer / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014230:Triazoles / Q000627:therapeutic use; D065819:Voriconazole; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D004365:Drugs, Chinese Herbal; D007166:Immunosuppressive Agents; D011743:Pyrimidines; D014230:Triazoles; C583081:ru-yi-jin-huang-san; D003561:Cytarabine; D008942:Mitoxantrone; D065819:Voriconazole; D003630:Daunorubicin